The Company continues to expect total revenue for the fiscal year ended December 31, 2025, to approximate $732 million, reflecting growth of approximately 20% compared to full year 2024. This includes surgical revenue of approximately $657 million and approximately $75 million of EOS revenue. The Company also continues to anticipate adjusted EBITDA of approximately $75 million, which will contribute to positive free cash flow for the full year 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATEC:
- ATEC Earnings this Week: How Will it Perform?
- Alphatec likely to benefit as Stryker exits spinal implants, says Lake Street
- Alphatec price target raised to $21 from $20 at Barclays
- Alphatec price target raised to $19 from $16 at Jefferies
- J&J to acquire Intra-Cellular, Clearwater to buy Enfusion: Morning Buzz